Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy
Photodynamic therapy (PDT) has shown promise as an effective treatment modality for
cancers and other localized diseases, such as age-related macular degeneration and …
cancers and other localized diseases, such as age-related macular degeneration and …
Fighting hypoxia to improve PDT
L Larue, B Myrzakhmetov, A Ben-Mihoub… - Pharmaceuticals, 2019 - mdpi.com
Photodynamic therapy (PDT) has drawn great interest in recent years mainly due to its low
side effects and few drug resistances. Nevertheless, one of the issues of PDT is the need for …
side effects and few drug resistances. Nevertheless, one of the issues of PDT is the need for …
A microneedle patch with self-oxygenation and glutathione depletion for repeatable photodynamic therapy
Photodynamic therapy (PDT) has attained extensive attention as a noninvasive tumor
treatment modality. However, the hypoxia in solid tumors, skin phototoxicity of “always on” …
treatment modality. However, the hypoxia in solid tumors, skin phototoxicity of “always on” …
Recent advances in strategies for overcoming hypoxia in photodynamic therapy of cancer
The selectivity of photodynamic therapy (PDT) derived from the tailored accumulation of
photosensitizing drug (photosensitizer; PS) in the tumor microenvironment (TME), and from …
photosensitizing drug (photosensitizer; PS) in the tumor microenvironment (TME), and from …
Hypoxia is important in the biology and aggression of human glial brain tumors
SM Evans, KD Judy, I Dunphy, WT Jenkins… - Clinical Cancer …, 2004 - AACR
We investigated whether increasing levels of tissue hypoxia, measured by the binding of
EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2, 2, 3, 3, 3-pentafluoropropyl) acetamide] or by …
EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2, 2, 3, 3, 3-pentafluoropropyl) acetamide] or by …
Fluence rate as a modulator of PDT mechanisms
BW Henderson, TM Busch… - Lasers in Surgery and …, 2006 - Wiley Online Library
Abstract Background and Objectives Molecular oxygen in the tissue to be treated by
photodynamic therapy (PDT) is critical for photodynamic cell killing. The fluence rate of PDT …
photodynamic therapy (PDT) is critical for photodynamic cell killing. The fluence rate of PDT …
Synergism of epidermal growth factor receptor–targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo
MG del Carmen, I Rizvi, Y Chang… - Journal of the …, 2005 - academic.oup.com
Background: Epithelial ovarian cancer often develops resistance to standard treatments,
which is a major reason for the high mortality associated with the disease. We examined the …
which is a major reason for the high mortality associated with the disease. We examined the …
Tumor vascular microenvironment determines responsiveness to photodynamic therapy
AL Maas, SL Carter, EP Wileyto, J Miller, M Yuan, G Yu… - Cancer research, 2012 - AACR
The efficacy of photodynamic therapy (PDT) depends upon the delivery of both
photosensitizing drug and oxygen. In this study, we hypothesized that local vascular …
photosensitizing drug and oxygen. In this study, we hypothesized that local vascular …
A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis
SM Hahn, DL Fraker, R Mick, J Metz, TM Busch… - Clinical cancer …, 2006 - AACR
Purpose: A previous phase I trial of ip photodynamic therapy established the maximally
tolerated dose of Photofrin (Axcan Pharma, Birmingham, AL)-mediated photodynamic …
tolerated dose of Photofrin (Axcan Pharma, Birmingham, AL)-mediated photodynamic …
Clinical pharmacokinetics of the PDT photosensitizers porfimer sodium (Photofrin), 2‐[1‐hexyloxyethyl]‐2‐devinyl pyropheophorbide‐a (Photochlor) and 5‐ALA …
DA Bellnier, WR Greco, GM Loewen… - Lasers in Surgery …, 2006 - Wiley Online Library
Abstract Background and Objectives Photodynamic therapy (PDT) uses a photosensitizer
activated by light, in an oxygen‐rich environment, to destroy malignant tumors. Clinical trials …
activated by light, in an oxygen‐rich environment, to destroy malignant tumors. Clinical trials …